Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Lung Cancer

Free Subscription Articles published in Cancer Cell Retrieve available abstracts of 38 articles: HTML format

Single Articles

May 2025
1. TENG M, Guo J, Xu X, Ci X, et al
   Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.
   Cancer Cell. 2025;43:891-904.
   PubMed     Abstract available
   
   
   
2. LI Y, Oser MG
   A circular RNA in neuroendocrine carcinomas.
   Cancer Cell. 2025;43:812-814.
   PubMed     Abstract available
   
   
   February 2025
3. CHEN H, Deng C, Gao J, Wang J, et al
   Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer.
   Cancer Cell. 2025 Feb 14:S1535-6108(25)00030-3. doi: 10.1016/j.ccell.2025.
   PubMed     Abstract available
   
   
   
4. HENICK BS, Taylor AM, Nakagawa H, Wong KK, et al
   Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy.
   Cancer Cell. 2025;43:178-194.
   PubMed     Abstract available
   
   
   December 2024
5. HANGGI K, Li J, Gangadharan A, Liu X, et al
   Interleukin-1alpha release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity.
   Cancer Cell. 2024;42:2015-2031.
   PubMed     Abstract available
   
   
   October 2024
6. FU M, Zhao J, Zhang L, Sheng Z, et al
   Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade.
   Cancer Cell. 2024 Oct 9:S1535-6108(24)00360-X. doi: 10.1016/j.ccell.2024.
   PubMed     Abstract available
   
   
   September 2024
7. XU J, Wan R, Cai Y, Cai S, et al
   Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.
   Cancer Cell. 2024;42:1598-1613.
   PubMed     Abstract available
   
   
   August 2024
8. MCRAE HM, Hargreaves DC
   Transcription factor dependencies identify BAF-dependent cancers.
   Cancer Cell. 2024;42:1326-1328.
   PubMed     Abstract available
   
   
   
9. HE T, Xiao L, Qiao Y, Klingbeil O, et al
   Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies.
   Cancer Cell. 2024;42:1336-1351.
   PubMed     Abstract available
   
   
   July 2024
10. DUPLAQUET L, So K, Ying AW, Pal Choudhuri S, et al
    Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer.
    Cancer Cell. 2024 Jul 17:S1535-6108(24)00237-X. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    June 2024
11. ZHOU Q, Pan Y, Yang X, Zhao Y, et al
    Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial.
    Cancer Cell. 2024 Jun 11:S1535-6108(24)00192-2. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    May 2024
12. MCGINNIS CS, Miao Z, Superville D, Yao W, et al
    The temporal progression of lung immune remodeling during breast cancer metastasis.
    Cancer Cell. 2024 May 24:S1535-6108(24)00167-3. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
13. FINLAY JB, Ireland AS, Hawgood SB, Reyes T, et al
    Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer.
    Cancer Cell. 2024 May 20:S1535-6108(24)00164-8. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
14. LIU SY, Feng WN, Wu YL
    Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
    Cancer Cell. 2024;42:727-731.
    PubMed     Abstract available
    
    
    March 2024
15. HU F, Lito P
    Insights into how adeno-squamous transition drives KRAS inhibitor resistance.
    Cancer Cell. 2024;42:330-332.
    PubMed     Abstract available
    
    
    
16. HE XY, Gao Y, Ng D, Michalopoulou E, et al
    Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment.
    Cancer Cell. 2024;42:474-486.
    PubMed     Abstract available
    
    
    February 2024
17. TONG X, Patel AS, Kim E, Li H, et al
    Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
    Cancer Cell. 2024 Feb 20:S1535-6108(24)00036-9. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
18. LIU NN, Yi CX, Wei LQ, Zhou JA, et al
    The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
    Cancer Cell. 2024;42:318-322.
    PubMed    
    
    
    
19. HUANG DD, Yang JC
    Re-inventing a better wheel? Serplulimab for squamous cell lung cancer.
    Cancer Cell. 2024;42:172-174.
    PubMed     Abstract available
    
    
    
20. BENGUIGUI M, Cooper TJ, Kalkar P, Schif-Zuck S, et al
    Interferon-stimulated neutrophils as a predictor of immunotherapy response.
    Cancer Cell. 2024;42:253-265.
    PubMed     Abstract available
    
    
    
21. NABET BY, Hamidi H, Lee MC, Banchereau R, et al
    Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
    Cancer Cell. 2024 Feb 9:S1535-6108(24)00015-1. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    January 2024
22. HEEKE S, Gay CM, Estecio MR, Tran H, et al
    Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.
    Cancer Cell. 2024 Jan 24:S1535-6108(24)00006-0. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
23. MEMON D, Schoenfeld AJ, Ye D, Fromm G, et al
    Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
    Cancer Cell. 2024 Jan 9:S1535-6108(23)00441-5. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
24. CORDS L, Engler S, Haberecker M, Ruschoff JH, et al
    Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer.
    Cancer Cell. 2024 Jan 8:S1535-6108(23)00449-X. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    December 2023
25. ZHOU C, Hu Y, Arkania E, Kilickap S, et al
    A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).
    Cancer Cell. 2023 Dec 21:S1535-6108(23)00432-4. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
26. DAYTON TL, Alcala N, Moonen L, den Hartigh L, et al
    Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites.
    Cancer Cell. 2023;41:2083-2099.
    PubMed     Abstract available
    
    
    
27. GERSTBERGER S, Ganesh K
    NEN in a dish: A patient-derived organoid biobank illuminates potential novel therapeutic opportunities for neuroendocrine neoplasms.
    Cancer Cell. 2023;41:2014-2016.
    PubMed     Abstract available
    
    
    
28. CHEN CC, Tran W, Song K, Sugimoto T, et al
    Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.
    Cancer Cell. 2023;41:2066-2082.
    PubMed     Abstract available
    
    
    November 2023
29. JIAGGE E, Jin DX, Newberg JY, Perea-Chamblee T, et al
    Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
    Cancer Cell. 2023;41:1963-1971.
    PubMed     Abstract available
    
    
    
30. RAHAL Z, Kadara H
    Beyond bacteria: How the intratumor mycobiome modulates lung adenocarcinoma progression.
    Cancer Cell. 2023;41:1846-1848.
    PubMed     Abstract available
    
    
    October 2023
31. RODILLA AM, Valanparambil RM, Mack PC, Hsu CY, et al
    Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer.
    Cancer Cell. 2023 Oct 13:S1535-6108(23)00350-1. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
32. PAN Y, Zhang JT, Gao X, Chen ZY, et al
    Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
    Cancer Cell. 2023;41:1763-1773.
    PubMed     Abstract available
    
    
    
33. LI Z, Lu S
    Integrating minimal residual disease monitoring into clinical practice for NSCLC: Is the era upon us?
    Cancer Cell. 2023;41:1699-1701.
    PubMed     Abstract available
    
    
    September 2023
34. ZHU M, Kim J, Deng Q, Ricciuti B, et al
    Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.
    Cancer Cell. 2023 Sep 26:S1535-6108(23)00322-7. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
35. LIU NN, Yi CX, Wei LQ, Zhou JA, et al
    The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
    Cancer Cell. 2023 Sep 19:S1535-6108(23)00288-X. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
36. TOPP BG, Channavazzala M, Mayawala K, De Alwis DP, et al
    Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
    Cancer Cell. 2023;41:1680-1688.
    PubMed     Abstract available
    
    
    
37. MEGYESFALVI Z, Heeke S, Drapkin BJ, Solta A, et al
    Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies.
    Cancer Cell. 2023;41:1535-1540.
    PubMed     Abstract available
    
    
    
38. CHEN K, Yang F, Shen H, Wang C, et al
    Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
    Cancer Cell. 2023 Sep 1:S1535-6108(23)00286-6. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.